EGFR and non-small cell lung carcinoma: For example, NSCLC driven by EGFR mutations comprises approximately 15% of all NSCLC in North America; EGFR exon 19del or L858R substitution mutations are the most frequently reported (approximately 85% of all EGFR‐mutated NSCLC) [15].